Korean J Gastroenterol.  2011 Mar;57(3):141-143. 10.4166/kjg.2011.57.3.141.

Pediatric Obesity and Non-alcoholic Fatty Liver Disease: Is It Real Problematic?

• Kim SG

• KMID: 1128351
• DOI: http://doi.org/10.4166/kjg.2011.57.3.141

Abstract

No abstract available.

MeSH Terms

Citric Acid Cycle/physiology
Cytochrome P-450 Enzyme System/metabolism
Fatty Liver/diagnosis/pathology/ultrasonography
Humans
Obesity/*complications
Severity of Illness Index

Reference

References

1. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol. 2002; 34:255–262.

2. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002; 17:1136–1143.

3. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98:960–967.

4. Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol. 2003; 18:124–138.

5. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55:434–438.

6. Sanyal AJ. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002; 123:1705–1725.

7. Lobstein T, Baur L, Uauy R IASO International Obesity TaskForce. Obesity in children and young people: a crisis in public health. Obes Rev. 2004; 5(Suppl 1):4–104.

8. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006; 295:1549–1555.

9. Cecil JE, Watt P, Murrie IS, et al. Childhood obesity and socioeconomic status: a novel role for height growth limitation. Int J Obes (Lond). 2005; 29:1199–1203.

10. Willms JD, Tremblay MS, Katzmarzyk PT. Geographic and demographic variation in the prevalence of overweight Canadian children. Obes Res. 2003; 11:668–673.

11. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2000; 30:48–53.

12. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005; 42:641–649.

13. Nobili V, Marcellini M, Devito R, et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006; 44:458–465.

14. Stettler N, Zemel BS, Kumanyika S, Stallings VA. Infant weight gain and childhood overweight status in a multicenter, cohort study. Pediatrics. 2002; 109:194–199.

15. Reilly JJ, Armstrong J, Dorosty AR, et al. Avon Longitudinal Study of Parents and Children Study Team. Early life risk factors for obesity in childhood: cohort study. BMJ. 2005; 330:1357.

16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94:2467–2474.

17. Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41:1313–1321.

18. Jee SJ, Kim YJ, Song SY, Paik SS. Clinical correlates of histopathology, clinical manifestation and ultrasonographic grades in pediatric NAFLD. Korean J Gastroenterol. 2011; 57:158–165.

19. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998; 114:842–845.

20. Mohn A, Catino M, Capanna R, Giannini C, Marcovecchio M, Chiarelli F. Increased oxidative stress in prepubertal severely obese children: effect of a dietary restriction-weight loss program. J Clin Endocrinol Metab. 2005; 90:2653–2658.

21. Shea S, Aymong E, Zybert P, et al. Obesity, fasting plasma insulin, and C-reactive protein levels in healthy children. Obes Res. 2003; 11:95–103.

22. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006; 118:1388–1393.

23. Molleston JP, White F, Teckman J, Fitzgerald JF. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol. 2002; 97:2460–2462.

24. Suzuki D, Hashimoto E, Kaneda K, Tokushige K, Shiratori K. Liver failure caused by non-alcoholic steatohepatitis in an obese young male. J Gastroenterol Hepatol. 2005; 20:327–329.

25. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003; 38:1008–1017.

26. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004; 39:188–196.

27. Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2010; 32:1211–1221.